Pelaia Girolamo, Maselli Rosario, Gallelli Luca
Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University "Magna Graecia" of Catanzaro, Campus Universitario "S. Venuta", Viale Europa, Località, Germaneto, 88100 Catanzaro, Italy.
Department of Health Science, Section of Pharmacology, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
Multidiscip Respir Med. 2014 Dec 8;9(1):64. doi: 10.1186/2049-6958-9-64. eCollection 2014.
Chronic obstructive pulmonary disease (COPD) is a widespread respiratory disorder, usually characterized by progressive and poorly reversible airflow limitation. Inhaled long-acting bronchodilators, namely LABA (long-acting β2-adrenergic agonists) and LAMA (long-acting muscarinic receptor antagonists) are the mainstay of COPD treatment. Because the symptoms of many patients with COPD do not satisfactorily improve by using a single, either LABA or LAMA bronchodilator, the synergism of action resulting from the combination of the different bronchodilating mechanisms activated by LABA and LAMA, respectively, can significantly contribute to a better disease control. Based on these clinical and pharmacological considerations, several LABA/LAMA fixed-dose combinations have been developed and experimentally evaluated. Within such a context, the drug co-formulation containing indacaterol and glycopyrronium is probably the LABA/LAMA association which has been most extensively studied during the last few years.
慢性阻塞性肺疾病（COPD）是一种广泛存在的呼吸系统疾病，通常以进行性且可逆性差的气流受限为特征。吸入长效支气管扩张剂，即长效β2肾上腺素能激动剂（LABA）和长效毒蕈碱受体拮抗剂（LAMA）是COPD治疗的主要药物。由于许多COPD患者使用单一的LABA或LAMA支气管扩张剂时症状改善不明显，分别由LABA和LAMA激活的不同支气管扩张机制联合产生的协同作用可显著有助于更好地控制疾病。基于这些临床和药理学考虑，已开发并进行了几种LABA/LAMA固定剂量组合的实验评估。在此背景下，含有茚达特罗和格隆溴铵的药物复方制剂可能是过去几年中研究最广泛的LABA/LAMA联合用药。
